WO2008023874A1 - Manufacturing method of activated lymphocytes for immunotherapy - Google Patents
Manufacturing method of activated lymphocytes for immunotherapy Download PDFInfo
- Publication number
- WO2008023874A1 WO2008023874A1 PCT/KR2007/001893 KR2007001893W WO2008023874A1 WO 2008023874 A1 WO2008023874 A1 WO 2008023874A1 KR 2007001893 W KR2007001893 W KR 2007001893W WO 2008023874 A1 WO2008023874 A1 WO 2008023874A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- lymphocytes
- antibody
- activated lymphocytes
- culture
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 157
- 238000009169 immunotherapy Methods 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 120
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 40
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 37
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 31
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 26
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 23
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 20
- 239000011886 peripheral blood Substances 0.000 claims abstract description 20
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 102000000588 Interleukin-2 Human genes 0.000 claims description 39
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 25
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 25
- 238000007710 freezing Methods 0.000 claims description 25
- 230000008014 freezing Effects 0.000 claims description 25
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 16
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 16
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 16
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 13
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 13
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 10
- 238000005138 cryopreservation Methods 0.000 claims description 9
- 229960003130 interferon gamma Drugs 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000013028 medium composition Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 abstract description 16
- 230000001093 anti-cancer Effects 0.000 abstract description 15
- 210000000822 natural killer cell Anatomy 0.000 abstract description 13
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 abstract description 11
- 210000004405 cytokine-induced killer cell Anatomy 0.000 abstract description 10
- 230000002062 proliferating effect Effects 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 239000002771 cell marker Substances 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 31
- 108091007433 antigens Proteins 0.000 description 31
- 239000002609 medium Substances 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 16
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 13
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000003755 preservative agent Substances 0.000 description 12
- 230000002335 preservative effect Effects 0.000 description 12
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002955 immunomodulating agent Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 2
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003287 lymphocyte surface marker Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 241000608867 Leucogenes Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000388 leucogen effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940101738 pentastarch Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Definitions
- the present invention relates to a method for preparing activated lymphocytes, and more particularly to a method for preparing activated lymphocytes, which can be used as cellular immunotherapeutic agents either by isolating lymphocytes from human peripheral blood, proliferating and activating the isolated lymphocytes in large amounts in vitro and administering the activated lymphocytes to the person from which the lymphocytes originated, or by cryopreserving the activated lymphocytes, and administering the cryopreserved lymphocytes to the person from which the lymphocytes originated, when the person has a disease against which the administration of the immune cells is required.
- cellular immunotherapeutic agents either by isolating lymphocytes from human peripheral blood, proliferating and activating the isolated lymphocytes in large amounts in vitro and administering the activated lymphocytes to the person from which the lymphocytes originated, or by cryopreserving the activated lymphocytes, and administering the cryopreserved lymphocytes to the person from which the lymphocytes originated, when the person has a disease
- Human immune cells include natural killer (NK) cells and T lymphocytes, which can recognize and eliminate transformed cells such as cancer cells or virus- infected cells. Thus, the use of function of such cells will have preventive and therapeutic effects against these diseases.
- NK natural killer
- T lymphocytes T lymphocytes
- the use of function of such cells will have preventive and therapeutic effects against these diseases.
- it is difficult for immune cells to show sufficient anticancer effects because the immune system is weakened due to various anticancer therapies, including surgery, anticancer drug therapy and radiation therapy, so as to weaken the function of immune cells or to significantly reduce the number of immune cells. For this reason, if immune cells from a patient are proliferated and activated in vitro in large amounts, and then administered to the autologous patient, it is possible to expect high anticancer effects.
- An activated lymphocyte is a cellular immunotherapy product for treating cancer by proliferating and activating human blood immune cells in vitro in large amounts and administering the activated immune cells to the autologous person, and it is an individually tailored anticancer immunotherapeutic agent for inducing in vivo immune by activating the immune cells of the autologous patient, like an anticancer immunotherapeutic agent comprising dendritic cells.
- cytotoxic T lymphocytes CTL
- MHC class I- deficient cancer cells are highly sensitive to natural killer (NK) cells [Pawelec et al., 2004].
- NK cells can eliminate cancer cells and virus-infected cells without recognizing antigens [Albertsson et al., 2003; Colucci et al., 2003; Smyth et al., 2002].
- NK cells The activity of NK cells is regulated by a balance of signals from activating signals and inhibitory signals [Farag et al., 2003].
- the most well activating ligands are NKG2D ligands.
- MICA/B MHC class l-related chain A and B
- ULBPs UL-16 binding proteins
- the expression of the NKG2D ligands is induced by stresses, and these ligands show various expression patterns in various cancer cell lines [Watzl et al., 2003].
- NKG2D ligands have the capability to label stressed or transformed cells means that the sensitivity of cancer cells to NK cells can be controlled by the regulation of expression of activating ligands. Because the NKG2D ligands can increase sensitivity to NK cells, cancer cells with a high expression of NKG2D ligands can be eliminated, even though the expression of MHC class I is normal [Raulet et al., 2003]. Thus, if the expression of NKG2D ligands can be increased, the anticancer therapeutic effects of NKG2D receptor- expressing cells such as NK, NKT, CD8+T and y ⁇ T cells can be further increased.
- LAK cells lymphokine-activated killer cells; NK cells activated by IL-2
- NK cells activated by IL-2 NK cells activated by IL-2
- the use of the LAK cells in clinical applications was limited, because the anticancer cytotoxicity of the LAK cells was relatively weak and it was difficult to secure the cells in large amounts.
- CIK cytokine-induced killer cells
- MS Dilber et al. developed technology of culturing CD3- CD56+ in large amounts by culturing peripheral blood monocytes in an anti-CD3 antibody and IL-2 [Carlens et al., 2001].
- the cultured cells are called "CINK (cytokine-induced natural killer) cells", which have high proliferation rate compared to the existing LAK cells.
- CINK cytokine-induced natural killer cells
- CD3-CD56+ cells could be cultured in large amounts only in CellGro SCGM media supplemented with an anti-CD3 antibody and IL-2.
- CD4+CD25+ regulatory T cells are present in peripheral blood monocytes (PBMCs) of normal persons at a ratio of less than 5% and suppress the proliferation of T cells in vitro [K.E. Earle et al., 2005]. Furthermore, CIK cells cultured with IL-2 in vitro can induce the proliferation of CD4+CD25+ regulatory T cells that secrete a large amount of IL-10, thus suppressing the proliferation of CTL and reducing the cytotoxicity of CTL [Jan Schmidt et al., 2004].
- PBMCs peripheral blood monocytes
- CD4+CD25+ regulatory T cells reduce the amount of an NKG2D receptor that is expressed in CIK or NK cells, and TGF- ⁇ produced by activated CD4+CD25+ regulatory T cells inhibits the cytotoxicity of NK cells [Francois G et al., 2005]. Accordingly, in the present invention, the ratio of CD4+CD25+ regulatory T cells in autologous activated lymphocytes differentiated and proliferated from PBMC is remarkably reduced to 5%, thus improving the in vivo function of the autologous activated lymphocytes.
- CD56+ and NKG2D+ cells having excellent killing ability against tumor cells and virus-infected cells can be prepared in large amounts by culturing lymphocytes isolated from human peripheral blood, in the presence of interleukin-2 (IL-2), interferon-gamma (IFN- ⁇ ) and an anti-CD3 antibody, thereby completing the present invention.
- IL-2 interleukin-2
- IFN- ⁇ interferon-gamma
- Another object of the present invention is to provide a cellular immunotherapeutic composition comprising, as active ingredients, activated lymphocytes proliferated according to said method.
- FIG. 1 shows measurement results for the number of activated lymphocytes at 6 days, 10 days, 15 days and 21 days of culture.
- FIG. 2 shows graphs obtained by analyzing surface antigens CD3 and
- CD56 in activated lymphocytes of each test group using flowcytometry is a measure of CD56 in activated lymphocytes of each test group using flowcytometry.
- FIG. 3 shows graphs obtained by analyzing surface antigens NKG2D and CD56 in activated lymphocytes of each test group using flowcytometry.
- FIG. 4 shows graphs obtained by analyzing surface antigens CD16 and CD56 in activated lymphocytes of each test group using flowcytometry.
- FIG. 5 shows graphs obtained by analyzing surface antigens CD3 and CD56, surface antigens NKG2D and CD56 and surface antigens CD16 and CD56 in activated lymphocytes using flowcytometry before and after freezing the activated lymphocytes.
- FIG. 6 shows the CD4- and CD25-positive cells in the CIK (cytokine- induced killer) cells of normal persons, cultured in a medium supplemented with an anti-CD3 antibody and IL-2.
- CIK cytokine- induced killer
- FIG. 7 shows results obtained by analyzing surface antigens CD4 and CD25 in activated lymphocytes using flowcytometry at 0 days, 14 days and 21 days of culture.
- a method for preparing activated lymphocytes comprising the steps of: (1) collecting and isolating lymphocytes from peripheral blood; (2) culturing the lymphocytes in vitro in the presence of interleukin-2 (IL-2), interferon-gamma (IFN- ⁇ ) and an anti-CD3 antibody to prepare activated lymphocytes; (3) cryopreservating the activated lymphocytes for a given period of time; and (4) thawing and restoring the lymphocytes of the cryopreservation step.
- the steps (3) and (4) are used when the long-term storage of the activated lymphocytes prepared through the steps (1) and (2) is required.
- the step (1) of the method of the present invention is a step of collecting and isolating lymphocytes from peripheral blood, in which the lymphocytes are collected from the peripheral blood of a person with disease or a healthy person.
- the collection of blood from arm veins is preferred because it is convenient and easy, but any material can be used as long as it contains lymphocytes.
- the amount of peripheral blood collected is preferably about 0.001-500 ml, and more preferably about 10-100 ml.
- Heparin, EDTA or citric acid may be added to the peripheral blood collected in the step (1), such that the coagulation of the blood does not occur.
- the activated lymphocytes of the present invention can be obtained by isolating lymphocytes from the collected peripheral blood and proliferating and activating the isolated lymphocytes through in vitro culture.
- the step (2) of the method according to the present invention is a culture step of activating and proliferating the lymphocytes isolated in the step (1).
- the method of culturing the lymphocytes collected in the step (1) is not specifically limited, but is preferably carried out in the presence of IL-2, IFN- ⁇ or an anti-CD3 antibody alone, or combinations thereof. In this case, it is most preferable to culture the lymphocytes in the presence of a combination of IL-2, IFN- ⁇ and an anti-CD3 antibody, because this can show an excellent anticancer effect compared to the case of culturing the lymphocytes in the presence of IL-2, IFN- ⁇ or an anti-CD3 antibody alone.
- antigen-specific activated lymphocytes can also be obtained by inducing antigen-specific T lymphocytes using a suitable antigen and then adding a CD3 antibody, a CD3 antibody or various mitogen thereto.
- the antigen it is possible to use a purified antigen, an extract from cancer cells or viruses, a cancer cell or virus itself, or a pseudo-antigen having cross-reactivity therewith, and in this case, any material can be used as long as it has a function of proliferating and activating the lymphocytes.
- IL-15 may also be used instead of said IL-2 in the culture process.
- IL-2 and IFN- ⁇ which are used in the step (2) of the inventive method, are commercially available and are preferably used in a concentration of 1-2000 U/ml in the culture medium.
- IL-2 and IFN- ⁇ can be used after they are dissolved in generally widely used cell culture media, for example, physiological saline, phosphate buffer solution, RPMI-1640, DMEM, IMDM, AIM-V (GIBGO, USA), X- Vivo (Cambrex), LGM, KBM-306 (KohjinBio), CellGro (CellGenix), etc.
- IL-2 and IFN- ⁇ Once IL-2 and IFN- ⁇ are dissolved, they need to be stored in a cold or frozen state in order to prevent the activity thereof from decreasing.
- any medium can be used without any particular limitation as long as it is suitable for the culture of lymphocytes, and preferred examples thereof may include RPMI- 1640, DMEM, IMDM, AIM-V, X-Vivo, LGM, KBM and CellGro, particularly preferred being serum-free media, such as AIM-V, CellGro, KGM and X-Vivo.
- the culture medium, which is used in the step (2), preferably contains serum, because the serum-containing medium has an excellent proliferation effect.
- the serum not only commercially available bovine fetal serum or normal person's serum, but also autologous serum, may be used. Also, it is possible to use a serum-free medium.
- the culture of the lymphocytes can be carried out in a general cell culture system, for example, a CO 2 incubator.
- the concentration of CO 2 in the cell culture is in the range of 1-10 %, and preferably in the range of 3-7 %, and the culture temperature is in the range of 30-40 0 C , and preferably in the range of 35-38 ° C .
- the cell culture is preferably carried out for about 2-28 days because it is secured that the stimulus information of the anti-CD3 antibody is transferred to the cells.
- a culture period of 3-8 days is particularly preferable because it enables the stimulus information to be stably transferred to the cells and shows high culture efficiency. It is more preferable to observe the state of the cells with a microscope during the culture period to measure the number of the cells while adding a suitable amount of culture medium.
- the cells do not proliferate 1-4 days after the start of culture, but the proliferation of the cells is observed after that, and when the cells start to normally proliferate, the culture medium changes from orange to yellow.
- the amount of additional medium added is preferably about 0.1-5 times the amount of the culture medium to which the additional medium is to be added. Meanwhile, the addition of the additional medium is performed at an interval of 1-7 days, and preferably 2-4 days, in order to prevent the deterioration of the culture medium and the reduction of IL-2 activity.
- the cell culture in the step (2) of the inventive method can be initiated by suspending monocyte cells in a culture medium, containing IL-2 and IFN- ⁇ , and adding the anti-CD3 antibody to a culture container for immobilization. Furthermore, when various cytokines and mitogens, if necessary, are added to the culture medium, the efficiency of proliferation and activation of the lymphocytes will be further increased.
- the anti-CD3 antibody which is used for the stimulation of the lymphocyte cells, may be an antibody produced and purified from animals or cells, or a commercially available OKT-3 antibody. In addition to these antibodies, any antibody may be used without any particular limitation as long as it can stimulate the proliferation and activation of the lymphocytes. For example, an anti-CD28 antibody may also be used.
- the step (3) of the inventive method is a step of cryopreserving the activated lymphocytes for a given period of time.
- the lymphocytes to be preserved may be suspended in a cell preservative solution at a concentration suitably selected depending on the size thereof. It is required to suspend and cryopreserve the lymphocytes in the preservative solution at a density of 1x10 3 cells/ml to 1x10 10 cells/ml.
- the preservative solution is preferably used in the range of 0.1-1000 ml in view of convenience, and more preferably in the range of 0.5-100 ml.
- the cryspreservative solution for use in the step (3) of the inventive method may be a commercially available cell preservative solution or can be self- prepared for use in the step (3).
- the cell preservative solution may contain serum, polymer substances such as proteins or polysaccharides, and dimethyl sulfoxide (hereinafter, referred to as "DMSO") in a suitable buffer solution or basal medium, and all the listed substances are not required for the cells to be preserved.
- DMSO dimethyl sulfoxide
- a preservative solution enabling cell preservation has no limitation on the composition thereof.
- the lymphocytes are suspended in a suitable cell preservative solution and cryopreserved at low temperatures.
- the prepared cryopreservative solution may be stored in a refrigerator (4 0 C) after preparation until use.
- the activated lymphocytes are preferably CD56+ and NKG2D+ cells.
- the CD56+ is a killer cell marker
- the NKG2dD+ is a lymphocyte- activating receptor marker.
- the x-axis of graphs in FIG. 2 showing the results of Example 3 of the present invention is for lymphocytes labeled with CD3 (T-lymphocyte marker), and the y-axis is for lymphocytes labeled with CD56.
- CD3 T-lymphocyte marker
- CD56 lymphocytes labeled with CD56.
- Each of the graphs is divided into four sections for analysis, and among the four sections, the left upper section (region 01) indicates CD3-negative and CD56-positive natural killer cells (NK cells), and the right upper section (region 02) indicates CD3- and CD56-positive lymphocytes.
- the cells in these two sections (regions 01 and 02) are lymphocytes laving anticancer effects.
- FIG. 3 shows analysis results for the expression of an NKG2D receptor that is one of activating receptors known to be involved in the activation of lymphocytes, such as NK, NKT, CD8T and y ⁇ T cells.
- the x-axis of graphs in FIG. 3 is for lymphocytes labeled with NKG2D
- the y-axis is for lymphocytes labeled with CD56.
- Each graph was divided into four sections for analysis, and among the four sections, the left upper section (region 02) and the right lower section (region 04) indicate NKG2D-positive lymphocytes. Particularly, the right upper section indicates lymphocytes positive for both NKG2D and CD56.
- the ratio of NKG2D-positive lymphocytes in all test groups was higher than 90%, and NKG2D was positive in all most all killer cells (CD56-positive cells. From such results, it can be seen that activated lymphocytes cultured according to the preparation method of the present invention show high activity against tumor cells or virus-infected cells.
- the activated lymphocytes preferably further comprises, in addition to CD56+ and NKG2D+, CD16+.
- said CD16+ is an Fc gamma RIII marker.
- the x-axis of graphs in FIG. 4 showing the results of Example 3 is for lymphocytes labeled with CD16, and the y-axis is for lymphocytes labeled with CD56.
- Each graph was divided into four sections for analysis, and among the four sections, the right upper section (region P2) indicates lymphocytes positive for both CD16 and CD56.
- the CD16 surface antigen is known to induce antibody- dependent cell-mediated cytotoxocity (ADCC).
- the ratio of surface antigen-expressing cells in cells prepared according to the embodiment of the present invention was higher than 40% in all test groups, the cells prepared according to the present invention would show more potent anticancer effects compared to CIK cells which are known to express little or no CD16 surface antigen.
- the ratio of CD4+ and CD25+ in the activated lymphocytes is preferably 3-6 %, and more preferably less than 5%. It is known that CD4- and CD25-positive cells in the peripheral blood of cancer patients are 2.5 times larger than those in normal persons [Anna Maria Wolf et al, 2003]. Also, the CD4- and CD25-positive cells are known to increase in CIK (cytokine-induced killer) cells cultured from the peripheral blood of normal persons.
- CIK cytokine-induced killer
- the ratio of CD4- and CD25-positive cells was increased from 0.5 ⁇ 0.07% before culture to 35.5 ⁇ 8.4% after 14 days of culture (see FIG. 6) [Jan Schmit et al., 2004].
- the ratio of CD4- and CD25- positive cells in lymphocytes isolated from the peripheral blood of cancer patients was shown to be more than 10%, but it was reduced to a normal level of less than 5%, when the lymphocytes were cultured in the presence of IFN- ⁇ , an anti-CD3 antibody and IL-2 for 21 days (see FIG. 7).
- the anti-CD3 antibody is preferably immobilized to a culture container before use.
- the anti-CD3 antibody is preferably contained in a culture medium, but it is more preferably immobilized to culture container in view of lymphocyte-proliferation efficiency and operation easy.
- Culture container for immobilizing the antibody may include culture containers made of glass, polyurethane, polyolefin or polystyrene. Specifically, an easily available cell culture flask made of plastic can be used and the size thereof can be suitably selected.
- the immobilization of the antibody can be performed by adding a dilution of the anti-CD3 antibody to the culture container for immobilization and standing the antibody, for example, at 4-37 ° C for 2-24 hours.
- the anti-CD3 antibody is diluted in a physiological buffer saline such as sterilized phosphate buffer at a concentration of 0.1-30 ⁇ g/ml.
- the antibody can be stored in a refrigerator (4 "C) after immobilization until use.
- the liquid component is removed from the stored antibody dilution, and the remaining antibody may, if necessary, be washed with physiological buffer solution such as phosphate buffer solution at room temperature.
- physiological buffer solution such as phosphate buffer solution at room temperature.
- lymphocytes were cultured in AIM-V medium for G1 and G5, CellGro medium for G2 and G6, X-Vivo medium for G3 and G7, and KBM medium for G4 and G8.
- Measurement results for the number of activated lymphocytes at 21 days of culture showed that, when lymphocytes were cultured in a medium containing an anti-CD3 antibody (G1-G4), the number of activated lymphocytes increased by 168 times in average as compared to the number of lymphocytes at an early stage of culture, and when lymphocytes were cultured in an anti-CD3 antibody- immobilized flask (G5-G8), the number of activated lymphocytes increased by 338 times in average.
- the proliferation rate of the cells was about two times higher than the case of culture in the anti-CD3 antibody-containing medium AIM-V, and the mass culture of activated lymphocytes was possible in all CellGro, X-Vivo and KBM media.
- the proliferation and activation of cells were compared between the case of performing culture using the anti-CD3 antibody-immobilized flask and the case of performing culture using the medium containing the anti-CD3 antibody.
- the proliferation rate of the cells was about two times higher than the other case.
- the analysis of surface antigens CD3, CD16, CD56 and NKG2D at 21 days of culture showed that there was no difference according to culture conditions.
- the cryspreservation of the cells is preferably performed using a freezing tube or bag at a cell density of 0.5-10.0 x 10 7 cells/freezing tube or 0.05-10.0 x 10 10 cells/freezing bag.
- a freezing container in which the frozen cells of the present invention are to be preserved, may be a commercially available freezing cell freezing tube or bag, and the size thereof can be suitably selected.
- the number of the cells to be frozen is preferably 0.5-10.0 x 10 7 cells/freezing tube, and the number of freezing tubes is in the range of 2-1000 depending on the amount of blood collected.
- the number of the cells to be frozen is preferably 0.05- 10.0 x 10 10 cells/freezing bag, and the number of freezing bags is in the range of 1-10 depending on the amount of blood collected.
- the frozen cells are thawed, lysed and restored to the patient. In a special case, the cells may also be administered immediately after thawing and lysis.
- the cells are preserved for a maximum of 15 years, can be thawed, lysed and restored at a suitable point of time, if necessary, and can be cryopreserved for a long period of time.
- the cryopreserved cells may be stored according to any cell cryopreservation method known to one skilled in the art, but the cells can be stored for 15 years or longer, when the freezing tube or bag containing the cells is cooled to -70 to -90 °C at a rate of -1 °C/min using a controlled rate freezing system, and then transferred to and stored in a nitrogen tank.
- the cryopreservation of the present invention can be performed using a freezer, an ultra-low-temperature freezer or a nitrogen tank, but it is preferable to use a controlled rate freezing system in view of the stability and proliferation efficiency of lymphocytes.
- a controlled rate freezing system a commercially available system can be used and a system developed by a user may also be used.
- the frozen cells are stored in the controlled rate freezing system for 0-30 days, and preferably 0-7 days.
- the term "0 days" means that the period of cryopreservation in the controlled rate freezing system is 1-24 hours.
- the term "period" refers to a preliminary freezing period just before the activated lymphocytes are transferred to a nitrogen tank capable of storing the cells for a long period of time.
- the transfer of the cells from the controlled rate freezing system to the nitrogen tank may also be performed using any commercially available article, which can enter the nitrogen tank, including a can or a freezing tube box.
- a medium composition for the culture of activated lymphocytes comprising an anti-CD3 antibody, interleukin-2 (IL-2) and interferon-gamma (IFN- Y).
- the prior technology of culturing CD3-CD56+ cells can be performed only in a CellGro SCGM medium supplemented with the anti-CD3 antibody and IL-2, but in the present invention, large amounts of CD3-CD56+ cells can be cultured not only in CellGro SCGM medium, but also in AIM-V, CellGro DC, KBM-306 and X-Vivo media, in the presence of IL-2, the anti-CD3 antibody and IFN- ⁇ .
- a cellular immunotherapeutic composition comprising, as active ingredients, activated lymphocytes proliferated according to the preparation method of the present invention.
- the cellular immunotherapeutic agent is an anticancer immunotherapeutic agent for treating cancer by proliferating and activating human blood immune cells in large amounts in vitro and administering the activated cells to an autologous patient.
- an individually tailored anticancer therapeutic agent for inducing in vivo immune by activating the autologous immune cells of a patient like an anticancer immunotherapeutic agent comprising dendritic cells.
- the peripheral blood lymphocytes of not only normal persons, but also terminal cancer patients were cultured in the presence of an anti-CD3 antibody, IFN- ⁇ and IL-2, activated lymphocytes having substantially the same activity could proliferate in large amounts.
- the activated lymphocytes obtained according to the preparation method of the present invention were thawed and restored after they were cryopreserved for a long period of time, the viability and activity of the cells were maintained.
- the activated lymphocytes according to the present invention can be used as cellular immunotherapeutic agents either by isolating lymphocytes from the peripheral blood of a patient with disease or a healthy person, proliferating and activating the isolated lymphocytes in vitro and administering the activated lymphocytes to the autologous patient, or by cryopreserving the activated lymphocytes, and thawing and restoring the cryopreserved cells, when the person from which the lymphocytes originated has a disease against which the administration of the immune cells is required.
- the cellular immunotherapeutic composition of the present invention can be prepared in the form of general formulations known in the art, for example, an injectable solution, and can be surgically transplanted directly into a cancer site or can migrate into a cancer site after intravenous administration.
- the dose of the composition according to the present invention can vary depending on the type of disease, the route of administration, the age and sex of the patient, and the severity of the disease, the inventive composition is preferably administered at a dose of 1 x 10 7 -10 11 cells for average adults.
- highly effective toxic cells can be prepared in large amounts by culturing human peripheral blood lymphocytes in the presence of an anti-CD3 antibody, IFN- ⁇ and IL-2.
- the activated lymphocytes proliferated according to the preparation method of the present invention comprise both CD3-CD56+ (natural killer cell marker) cells that are the main component of LAK cells, and CD3+CD56+ cells that are the main components of CIK cells, and can be cultured in large amounts.
- CD3-CD56+ natural killer cell marker
- CD3+CD56+ cells that are the main components of CIK cells
- Example 1 Blood collection and isolation of lymphocytes
- peripheral blood was collected from human veins in an aseptic state.
- a blood collection tube or bag containing an anticoagulant such as heparin or EDTA was used as the blood collection container.
- the blood was injected into a 50-ml centrifugal tube and mixed well with the same amount of phosphate buffer saline (PBS).
- Histopaque-1077 solution Sigma was added to the 50-ml centrifugal tube such that the ratio of Histopaque-1077 to the PBS- diluted blood was 1 :2 to 1 :4.
- the PBS-diluted blood was added slowly to the centrifugal tube such that the liquid surface was not scattered.
- the mixture was centrifuged in conditions of revolution of 400 x g and room temperature, and the lymphocyte fraction was isolated. Then, the fraction was washed three times with a suitable amount of phosphate buffer saline. After the last centrifugal washing, the supernatant was removed, the lymphocyte precipitate was well suspended in phosphate buffer saline, and the number of the lymphocytes was measured using a trypan blue solution. As a result, the total cell number was 2.0 x 10 7 to 2.0 x 10 8 .
- Example 2 Preparation of anti-CD3 antibody-immobilized flask 10 ml of an anti-CD3 antibody solution (Orthoclone OKT3 injection manufactured by Ortho Biothech) prepared by adding the antibody to phosphate buffer saline at a concentration of 5 ⁇ g/ml was added to a culture flask having a bottom area of 225 cm 2 and was allowed to spread uniformly on the bottom surface. The next day, the antibody solution in the flask was sucked with a suction pump and washed three times with phosphate buffer saline, thus preparing an anti-CD3 antibody-immobilized flask.
- an anti-CD3 antibody solution Orthoclone OKT3 injection manufactured by Ortho Biothech
- the proliferation rate and activation of activated lymphocytes were compared between different culture conditions.
- a suspension of the lymphocytes was added to and mixed well with 50 ml of each of suitable media (G1 : AIM-V (GIBGO, USA); G2: CellGro (CellGenix); G3: KBM (Kohjin Bio); and G4: X-Vivo (Cambrex)), each containing 1000 U/ml IFN- ⁇ (Leucogen, LG Life Sciences) and 1-5 % human serum.
- G1 AIM-V
- G2 CellGro (CellGenix)
- G3 KBM (Kohjin Bio)
- G4 X-Vivo (Cambrex)
- each of the media was cultured in a cell culture flask in condition of 37 0 C and 5 % CO 2 .
- the culture medium in each flask was collected and transferred to a fresh 225-cm 2 T-flask, and 500 U/ml IL-2 (Proleukin, CHIRON) and 50 ng/ml anti-CD3 antibody (Orthoclone, Ortho Biotech) were added to each of the flasks. Meanwhile, the proliferation and activation of cells were compared between the case of performing culture using the anti-CD3 antibody-immobilized flask prepared in Example 2 and the case of performing culture using a medium containing the anti-CD3 antibody. After 5 days, the culture medium in each of the flasks was collected, and transferred to a 225-cm 2 T-flask.
- culture medium 50 ml of IL-2-containing culture medium (hereinafter, referred to as "culture medium”) was added to each flask and cultured at 37 0 C in the presence of 5% CO 2 . After 4 days, 100 ml of culture medium was added to each flask and cultured at 37 0 C in the presence of 5% CO 2 . During the culture period, 500 U/ml of interleukin-2 was added at an interval of 2-3 days.
- the number of flasks was increased in order to prevent the overcrowding of activated lymphocytes, and the cells were cultured at 37 0 C in the presence of 5% CO 2 for 21 days, thus obtaining 5.0 x 10 8 - 5.0 ⁇ 10 10 activated lymphocytes.
- FIGS. 2 to 4 show results obtained by analyzing surface antigens in activated lymphocytes using flowcytometry at 21 days of culture. Specifically, FIG. 2 shows analysis results for surface antigens CD3 and CD56, FIG. 3 shows analysis results for surface antigens NKG2D and CD56, and FIG. 4 shows analysis results for surface antigens CD16 and CD56.
- lymphocytes was cultured in AIM-V medium for G1 , CellGro medium for G2, X- Vivo medium for G3, and KBM medium for G4.
- surface antigens CD3 and CD56, surface antigens NKG2D and CD56 and surface antigens CD16 and CD56 in activated lymphocytes of each test group were analyzed at 21 days of culture using the anti-CD3 antibody-immobilized flask. As a result, the expression of each of the surface antigens was almost similar to the case of performing the culture of lymphocytes in a medium containing the anti-CD3 antibody.
- Example 4 Ratio of immune-suppressing T cell CD4+/CD25+ in activated lymphocytes
- the expression of CD4+/CD25+ cells that are immune-suppressing T cells, which induce immune tolerance was analyzed using flowcytometry at various points of time during culture.
- FIG. 7 shows results obtained by analyzing surface antigens CD4 and CD25 in activated lymphocytes using flowcytometry at 0 days, 14 days and 21 days of culture. As can be seen in FIG. 7, the expression level of CD4 and CD25 started to decrease with the passage of culture time, and was reduced to a normal level (less than 5%) after 21 days of culture.
- Example 5 Crvopreservation of activated lymphocytes
- the activated lymphocyte precipitate was mixed well with a cell preservative solution (medium 199 containing 7-15 % DMSO, 0.1-10 % penta-starch, 0.1-10 % heparin and 1-20 % albumin), and 1.0 ml of the lymphocyte solution was dispensed into each of 10 cell preservative tubes (Corning) according to culture conditions. Then, the cell preservative tubes were cooled to -90 " C at a rate of -1 o C/min using a controlled rate freezing system, and transferred to and stored in a nitrogen tank.
- Example 6 Thawing and analysis of crvopreserved activated lymphocytes After 60 days of storage, among the tubes cryopreserved in the step (4), three tubes per each of the test groups were taken, thawed in a constant- temperature water bath for 1-4 minutes, washed three times with media to remove the cell preservative solution, and suspended in the culture media. Then, the cells were measured for viability using a trypan blue solution, and the measurement results showed that the cell viability was in the range of 70-80% depending on culture conditions (see Table 1).
- each of suspensions of the activated lymphocytes cultured in various conditions as described above was cultured in a T75-cm 2 T-flask at 37 0 C in the presence of 5% CO 2 for 2-3 days, and then the viability of the activated lymphocytes was measured.
- the measurement results showed that the cell viability was higher than 95%.
- analysis results for surface antigens CD3, CD16, CD56 and NKG2D in the lymphocytes showed that the ratio of each surface antigen in the lymphocytes was almost similar between before and after the cryopreservation of the lymphocytes. From such results, it is considered that the long-term cryopreservation of the activated lymphocytes had no significant effect on the activity of the activated lymphocytes (see FIG. 5).
- Table 1 Cell viabilities of various test groups before and after cell cryopreservation
- the present invention in order to overcome the limitation of the prior methods for preparing activated lymphocytes, there is provided a preparation method by which CD56+ and NKG2D+ cells having excellent killing ability against tumor cells and virus-infected cells can be cultured in large amounts by culturing lymphocytes, isolated from human peripheral blood, in the presence of an anti- CD3 antibody, IL-2 and IFN- ⁇ .
- the activated lymphocytes proliferated and activated according to the inventive method can be used as cellular immunotherapeutic agents to greatly increase anticancer effects.
- activated lymphocytes obtained by proliferating and activating the peripheral blood lymphocytes of a healthy person can be frozen and preserved for a long period time, and some time later, when the person from which the activated lymphocytes originated has a disease against which the administration of immune cells is required, the preserved activated lymphocytes can be used as cellular immunotherapeutic agents to treat the disease.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/438,148 US20100233192A1 (en) | 2006-08-23 | 2007-04-18 | Manufacturing Method of Activated Lymphocytes for Immunotherapy |
CA002660518A CA2660518A1 (en) | 2006-08-23 | 2007-04-18 | Manufacturing method of activated lymphocytes for immunotherapy |
JP2009525477A JP2010501173A (en) | 2006-08-23 | 2007-04-18 | Method for producing activated lymphocytes for immunotherapy |
EP07746055A EP2052075A4 (en) | 2006-08-23 | 2007-04-18 | Manufacturing method of activated lymphocytes for immunotherapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20060079705 | 2006-08-23 | ||
KR10-2006-0079705 | 2006-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008023874A1 true WO2008023874A1 (en) | 2008-02-28 |
Family
ID=39106939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/001893 WO2008023874A1 (en) | 2006-08-23 | 2007-04-18 | Manufacturing method of activated lymphocytes for immunotherapy |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100233192A1 (en) |
EP (1) | EP2052075A4 (en) |
JP (1) | JP2010501173A (en) |
KR (1) | KR100943087B1 (en) |
CN (1) | CN101506356A (en) |
CA (1) | CA2660518A1 (en) |
RU (1) | RU2009110156A (en) |
WO (1) | WO2008023874A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011515084A (en) * | 2008-03-18 | 2011-05-19 | セールス・エンジニアリング・アクチェンゲゼルシャフト | Kit for collecting blood for producing stem cells, preferably peripheral blood |
CN102112600A (en) * | 2008-07-29 | 2011-06-29 | 株式会社绿十字 | Growth method for natural killer cells |
WO2013094988A1 (en) | 2011-12-22 | 2013-06-27 | Mogam Biotechnology Research Institute | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
EP2725100A1 (en) * | 2011-06-24 | 2014-04-30 | Kyushu University, National University Corporation | Method for amplifying nk cells |
CN104673751A (en) * | 2015-03-24 | 2015-06-03 | 刘慧玉 | Efficient CIK cell culturing method |
CN105274053A (en) * | 2015-11-26 | 2016-01-27 | 熊桂荣 | Preparation method for CIK cells with high cytotoxic activity |
CN111778211A (en) * | 2020-07-24 | 2020-10-16 | 深圳市人和生物科技有限公司 | Cell cryopreservation recovery re-culture method after DC-CTL culture interruption |
WO2021223274A1 (en) * | 2020-05-06 | 2021-11-11 | 青岛瑞思德生物科技有限公司 | In-vitro culture, induction, activation and cryopreservation method and cell bank establishment for immune cells |
CN114829585A (en) * | 2019-11-20 | 2022-07-29 | 吉爱希公司 | Composition for culturing T cells and method for culturing T cells using same |
US11766456B2 (en) | 2014-11-26 | 2023-09-26 | GC Cell Corporation | Method for culturing natural killer cells using T cells |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102939536A (en) * | 2009-11-14 | 2013-02-20 | 匡-宇·邱 | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
CN101914497B (en) * | 2010-07-19 | 2013-10-30 | 山东迪博生物技术有限公司 | Clinical N-CIK cell culture and quality control and identification kit and application |
CA2830080C (en) * | 2011-03-18 | 2021-10-26 | Jan Spanholtz | Generation of nk cells and nk-cell progenitors |
JP5856025B2 (en) * | 2012-08-02 | 2016-02-09 | 阿部 博幸 | Methods for obtaining monocytes or NK cells |
CN102839153A (en) * | 2012-09-13 | 2012-12-26 | 济南泰生生物技术有限公司 | Amplifying, freezing and storing and recovering method of activated lymphocyte with CD3+CD8+as major |
CN102899289B (en) * | 2012-10-24 | 2014-09-03 | 扬州维克斯生物科技有限公司 | Method for preparing super cytokine induced killer (CIK) cells |
CN105385656A (en) * | 2015-12-03 | 2016-03-09 | 王利利 | ECCE-CIK cell culture method and ECCE-CIK cell preparation |
CN105754940B (en) * | 2016-04-18 | 2020-09-22 | 广州市天河诺亚生物工程有限公司 | Application of traditional Chinese medicine component ginsenoside Rg3 in inducing CIK cell in-vitro culture |
CN106801036B (en) * | 2017-03-04 | 2019-01-08 | 青岛瑞思德生物科技有限公司 | A kind of biologically active peptide and the method with its external efficient amplification CIK cell |
WO2020189990A1 (en) * | 2019-03-15 | 2020-09-24 | (주)테라베스트 | Cell composition, method for producing same, and pharmaceutical composition for preventing or treating atopic disease comprising same |
KR102137954B1 (en) * | 2019-05-16 | 2020-07-27 | (주)녹십자셀 | Activated lymphocyte including cytokine induced killer cell and preparing method thereof |
CN111568975A (en) * | 2020-06-03 | 2020-08-25 | 广西医科大学附属肿瘤医院 | Application of golden camellia aqueous extract in preparation of medicine for T lymphocyte proliferation activation and tumor prevention |
CN112175904A (en) * | 2020-09-27 | 2021-01-05 | 北广再生医学科技(广东)有限公司 | Preparation method of killer cells induced by cytokines |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017567A1 (en) * | 1991-04-05 | 1992-10-15 | Regents Of The University Of Minnesota | Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets |
KR20020076593A (en) * | 2001-03-29 | 2002-10-11 | (주)라이프코드 | CD8α+ LYMPHOID DENDRITIC CELL DIFFERENTIATED FROM HUMAN HEMATOPOIETIC STEM CELL AND A METHOD FOR MASS-PRODUCING SAME |
KR20060007475A (en) * | 2004-07-20 | 2006-01-26 | (주)이노셀 | Process for its preperation, the lympocyte longterm cryopreservation for a cellular immunotherapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE373078T1 (en) * | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | SIMULTANEOUS STIMULATION AND CONCENTRATION OF CELLS |
US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
US7670781B2 (en) * | 2002-01-03 | 2010-03-02 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal |
-
2007
- 2007-04-18 WO PCT/KR2007/001893 patent/WO2008023874A1/en active Application Filing
- 2007-04-18 RU RU2009110156/10A patent/RU2009110156A/en not_active Application Discontinuation
- 2007-04-18 EP EP07746055A patent/EP2052075A4/en not_active Withdrawn
- 2007-04-18 JP JP2009525477A patent/JP2010501173A/en active Pending
- 2007-04-18 US US12/438,148 patent/US20100233192A1/en not_active Abandoned
- 2007-04-18 CN CNA2007800311437A patent/CN101506356A/en active Pending
- 2007-04-18 CA CA002660518A patent/CA2660518A1/en not_active Abandoned
- 2007-05-11 KR KR1020070046070A patent/KR100943087B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017567A1 (en) * | 1991-04-05 | 1992-10-15 | Regents Of The University Of Minnesota | Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets |
KR20020076593A (en) * | 2001-03-29 | 2002-10-11 | (주)라이프코드 | CD8α+ LYMPHOID DENDRITIC CELL DIFFERENTIATED FROM HUMAN HEMATOPOIETIC STEM CELL AND A METHOD FOR MASS-PRODUCING SAME |
KR20060007475A (en) * | 2004-07-20 | 2006-01-26 | (주)이노셀 | Process for its preperation, the lympocyte longterm cryopreservation for a cellular immunotherapy |
Non-Patent Citations (2)
Title |
---|
FERLAZZO G. ET AL.: "Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells", J. EXP. MED., vol. 195, no. 3, 2002, pages 343 - 351, XP008102562 * |
See also references of EP2052075A4 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8500712B2 (en) | 2008-03-18 | 2013-08-06 | Thankstem Srl | Kit for collecting blood, preferably peripheral blood, for the production of stem cells |
JP2011515084A (en) * | 2008-03-18 | 2011-05-19 | セールス・エンジニアリング・アクチェンゲゼルシャフト | Kit for collecting blood for producing stem cells, preferably peripheral blood |
CN102112600A (en) * | 2008-07-29 | 2011-06-29 | 株式会社绿十字 | Growth method for natural killer cells |
CN102112600B (en) * | 2008-07-29 | 2014-09-17 | Gc细胞治疗 | Growth method for natural killer cells |
EP2725100A4 (en) * | 2011-06-24 | 2015-01-07 | Univ Kyushu Nat Univ Corp | Method for amplifying nk cells |
US9404083B2 (en) | 2011-06-24 | 2016-08-02 | Kyushu University, National University Corporation | Method for amplifying NK cells |
EP2725100A1 (en) * | 2011-06-24 | 2014-04-30 | Kyushu University, National University Corporation | Method for amplifying nk cells |
EP2794859A4 (en) * | 2011-12-22 | 2015-05-27 | Mogam Biotechnology Inst | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
EP2794859A1 (en) * | 2011-12-22 | 2014-10-29 | Mogam Biotechnology Research Institute | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
WO2013094988A1 (en) | 2011-12-22 | 2013-06-27 | Mogam Biotechnology Research Institute | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
US11766456B2 (en) | 2014-11-26 | 2023-09-26 | GC Cell Corporation | Method for culturing natural killer cells using T cells |
CN104673751A (en) * | 2015-03-24 | 2015-06-03 | 刘慧玉 | Efficient CIK cell culturing method |
CN105274053A (en) * | 2015-11-26 | 2016-01-27 | 熊桂荣 | Preparation method for CIK cells with high cytotoxic activity |
CN105274053B (en) * | 2015-11-26 | 2019-03-26 | 嵊州明智科技服务有限公司 | A kind of preparation method of the CIK cell of high cytotoxic activity |
CN114829585A (en) * | 2019-11-20 | 2022-07-29 | 吉爱希公司 | Composition for culturing T cells and method for culturing T cells using same |
WO2021223274A1 (en) * | 2020-05-06 | 2021-11-11 | 青岛瑞思德生物科技有限公司 | In-vitro culture, induction, activation and cryopreservation method and cell bank establishment for immune cells |
CN111778211A (en) * | 2020-07-24 | 2020-10-16 | 深圳市人和生物科技有限公司 | Cell cryopreservation recovery re-culture method after DC-CTL culture interruption |
Also Published As
Publication number | Publication date |
---|---|
KR100943087B1 (en) | 2010-02-18 |
RU2009110156A (en) | 2010-09-27 |
JP2010501173A (en) | 2010-01-21 |
EP2052075A1 (en) | 2009-04-29 |
CA2660518A1 (en) | 2008-02-28 |
US20100233192A1 (en) | 2010-09-16 |
CN101506356A (en) | 2009-08-12 |
KR20080018089A (en) | 2008-02-27 |
EP2052075A4 (en) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100233192A1 (en) | Manufacturing Method of Activated Lymphocytes for Immunotherapy | |
US11766456B2 (en) | Method for culturing natural killer cells using T cells | |
AU2002257648B2 (en) | CD4+CD25+ regulatory T cells from human blood | |
EP1930414B1 (en) | Method for activation treatment of antigen-presenting cell | |
US8075921B2 (en) | Rapamycin-resistant T cells and therapeutic uses thereof | |
JP6359059B2 (en) | Handling of biological drugs containing living cells | |
KR20120091012A (en) | Process for production of natural killer cells | |
KR20220119611A (en) | Method for producing natural killer cells and composition thereof | |
JP4256431B2 (en) | Use of cytokines, cells and mitogens to inhibit graft-versus-host disease | |
DK2606125T3 (en) | CELLS EXPRESSING TH1 CHARACTERISTICS AND CYTOLYTIC PROPERTIES | |
PL218400B1 (en) | A vaccine for the treatment of type 1 diabetes in children, the use of a cell sorter and a method for proliferation of Treg cells producing a vaccine for the treatment of type 1 diabetes | |
EP1537203B1 (en) | USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12) | |
Hirano et al. | Graft hyporeactivity induced by immature donor-derived dendritic cells | |
AU2020248768A1 (en) | A method for providing immune cells | |
CA2529244C (en) | Rapamycin resistant t cells and therapeutic uses thereof | |
KR20230137392A (en) | Highly Potent M-CENK Cells and Methods | |
Zhang et al. | COMBINATION OF CALCINEURIN BLOCKER PLUS IL-2/FC TO INDUCE IMMUNE TOLERANCE. | |
Chen et al. | TOLEROGENIC ACTIVITY OF LIVER DENDRITIC CELLS IS REGULATED BY TLR4/B7-H1 PATHWAY. | |
Zerwes et al. | SYSTEMIC CHANGES IN T-CELL SUBSET COMPOSITIONS BY TRANSPLANTATION AND FTY720 TREATMENT: ANALYSIS OF MULTIPARAMETER FLOW CYTOMETRY DATA BY GENE ARRAY SOFTWARE. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780031143.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07746055 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007746055 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2660518 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009525477 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009110156 Country of ref document: RU Kind code of ref document: A |